HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
EYE ON CHINA
MicuRx expands global clinical trial program for oral antibiotic MRX-I

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, has initiated a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

The Phase 2 double-blind, multi-center, active comparator-controlled clinical study will enroll more than 200 patients with complicated skin and skin structure infections in China.

Concurrently, MicuRx is enrolling volunteers in a Phase 1 bridging study in Australia. The Phase 1 study will be performed in healthy subjects to assess the safety and pharmacokinetics of both single and multiple dose regimens of MRX-I in a non-Chinese population. This bridging study is designed to provide essential clinical data to support the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for a Phase 2 study of MRX-I to treat acute bacterial skin and skin structure infections.

"Leveraging the MicuRx US/China hybrid business strategy for discovery and development, we have implemented an aggressive clinical effort to secure global regulatory clearances for our proprietary antibiotics," commented Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx Pharmaceuticals, Inc. "The newly initiated clinical studies build on the Phase 1 trial in China that demonstrated MRX-I was safe and well tolerated in humans, with no signs of apparent myelosuppression. We believe that MRX-I has potential to be the best-in-class oxazolidinone antibiotic to address the growing global problem of multidrug resistance, and look forward to advancing this compound through development in an expeditious manner."

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
news Russia's only project to supply local high-tech anti-cancer drugs abroad continues with the first shipment to Vietnam
news Wheat Genome Sequencing Gets Major Boost
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy